Saei Hamzah M, Miller Samantha E, Pope Holly M, Hassan Ameer E
Department of Vascular Neurology, Rio Grande Regional Hospital, McAllen, TX, USA.
Department of Neuroscience, Valley Baptist Neuroscience Institute, Harlingen, TX, USA.
Interv Neuroradiol. 2024 Apr 9:15910199241245601. doi: 10.1177/15910199241245601.
Endovascular treatment devices require compatible guide catheters to navigate complex vessels and anatomy. The Fubuki XF Long Sheath guide catheter (Fubuki XF) was developed with a 0.090-inch internal diameter with hydrophilic coating, an atraumatic rounded tip, and enhanced trackability and support with gradual shaft transition zones.
We retrospectively analyzed a prospectively maintained database of neuroendovascular patients treated using Fubuki XF at our center (July 2022─May 2023). Baseline/procedural characteristics were collected. Outcomes of interest included technical success (procedure completion with Fubuki XF without alternative guide catheter use) and peri-procedural complications.
This study included 60 patients (43.3% [26/60] female; mean age: 69.6 ± 9.7) presenting with stenosis (45.0% [27/60]), unruptured aneurysms (31.7% [19/60]), ruptured aneurysm (1.7% [1/60]), arteriovenous fistula (5.0% [3/60]), arteriovenous malformation (3.3% [2/60]), chronic subdural hematoma (3.3% [2/60]), stroke/emboli (6.7% [4/60]), vasospasm (1.7% [1/60]), or carotid web (5.0% [1/60]). Fubuki XF was used to deliver endovascular treatment devices for stenting (43.3% [26/60]), flow diversion (23.3% [14/60]), embolization (11.7% [7/60]), coiling (10.0% [6/60]), balloon angioplasty (10.0% [6/60]), and mechanical thrombectomy (1.7% [1/60]). The Fubuki XF tip was placed in the internal carotid artery in 38.3% (23/60) of cases. Technical success was achieved in all cases. One V1 non-flow-limiting dissection (not related to Fubuki XF) and one failed closure occurred (1.7% [1/60] each). No iatrogenic strokes or intraprocedural ruptures occurred.
We used Fubuki XF to safely and effectively deliver a variety of compatible neuroendovascular devices. Fubuki XF was stable in all cases and locations, and there were no device-related complications or dissections.
血管内治疗设备需要兼容的引导导管来导航复杂的血管和解剖结构。吹雪XF长鞘引导导管（吹雪XF）的内径为0.090英寸，带有亲水涂层，尖端无创伤且呈圆形，通过逐渐过渡的轴区增强了可跟踪性和支撑性。
我们回顾性分析了在我们中心（2022年7月至2023年5月）使用吹雪XF治疗的神经血管内患者的前瞻性维护数据库。收集了基线/手术特征。感兴趣的结果包括技术成功（使用吹雪XF完成手术且未使用替代引导导管）和围手术期并发症。
本研究纳入了60例患者（女性占43.3%[26/60]；平均年龄：69.6±9.7岁），病因包括狭窄（45.0%[27/60]）、未破裂动脉瘤（31.7%[19/60]）、破裂动脉瘤（1.7%[1/60]）、动静脉瘘（5.0%[3/60]）、动静脉畸形（3.3%[2/60]）、慢性硬膜下血肿（3.3%[2/60]）、中风/栓子（6.7%[4/60]）、血管痉挛（1.7%[1/60]）或颈动脉蹼（5.0%[一说为1/60]）。吹雪XF用于输送血管内治疗设备进行支架置入（43.3%[26/60]）、血流导向（23.3%[14/60]）、栓塞（11.7%[7/60]）、弹簧圈栓塞（10.0%[6/60]）、球囊血管成形术（10.0%[6/60]）和机械取栓（1.7%[1/60]）。在38.3%（23/60）的病例中，吹雪XF的尖端置于颈内动脉。所有病例均取得技术成功。发生了1例V1非血流限制性夹层（与吹雪XF无关）和1例封堵失败（各占1.7%[1/60]）。未发生医源性中风或术中破裂。
我们使用吹雪XF安全有效地输送了各种兼容的神经血管内设备。吹雪XF在所有病例和位置均保持稳定，未出现与设备相关的并发症或夹层。
